Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: Outcomes from 133 consecutive newly diagnosed patients from a single institution

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 9, 2011, Pages 1404-1409

  DeZern, Amy E ^a,b   Sung, Anthony ^a   Kim, Sharon ^a   Smith, B Douglas ^a   Karp, Judith E ^a   Gore, Steven D ^a   Jones, Richard J ^a   Fuchs, Ephraim ^a   Luznik, Leo ^a   McDevitt, Michael ^a,b   Levis, Mark ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FLT3 ITD; Stem cell transplantation

Indexed keywords

CD135 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOTRANSPLANTATION; ARTICLE; CYTOGENETICS; FEMALE; GENE DUPLICATION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL;

ADULT; EARLY DETECTION OF CANCER; EARLY DIAGNOSIS; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051670412     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.02.003     Document Type: Article

References (25)

1. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med 1999, 341:1051-1062.
2. Burnett A.K., Wheatley K., Goldstone A.H., et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002, 118:385-400.
3. Byrd J.C., Mrozek K., Dodge R.K., et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002, 100:4325-4336.
4. Yanada M., Matsuo K., Emi N., Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005, 103:1652-1658.
5. Mrozek K., Heerema N.A., Bloomfield C.D. Cytogenetics in acute leukemia. Blood Rev 2004, 18:115-136.
6. Nakao M., Yokota S., Iwai T., et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996, 10:1911-1918.
7. Naoe T., Kiyoi H. Normal and oncogenic FLT3. Cell Mol Life Sci 2004, 61:2932-2938.
8. Kiyoi H., Yanada M., Ozekia K. Clinical significance of FLT3 in leukemia. Int J Hematol 2005, 82:85-92.
9. Yanada M., Matsuo K., Suzuki T., Kiyoi H., Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 2005, 19:1345-1349.
10. Frohling S., Schlenk R.F., Breitruck J., et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002, 100:4372-4380.
11. Murphy K.M., Levis M., Hafez M.J., et al. Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay. J Mol Diagn 2003, 5:96-102.
12. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
13. Karp J.E., Blackford A., Smith B.D., et al. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res 2010, 34:877-882.
14. Vaughan W.P., Karp J.E., Burke P.J. Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 1984, 64:975-980.
15. Castaigne S., Chevret S., Archimbaud E., et al. Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 2004, 104:2467-2474.
16. McCune J.S., Batchelder A., Deeg H.J., et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007, 13:853-862.
17. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
18. Luznik L., Fuchs E.J. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res 2010, 47:65-77.
19. Gale R.E., Hills R., Kottaridis P.D., et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 2005, 106:3658-3665.
20. Meshinchi S., Arceci R.J., Sanders J.E., et al. Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood 2006, 108:400-401.
21. Bornhauser M., Illmer T., Schaich M., et al. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood 2007, 109:2264-2265.
22. Fernandez H.F., Sun Z., Yao X., et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009, 361:1249-1259.
23. Santos F.P., Jones D., Qiao W., et al. Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. Cancer 2010.
24. Gaidzik V., Dohner K. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 2008, 35:346-355.
25. Mead A.J., Linch D.C., Hills R.K., et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007, 110:1262-1270.